GlobeNewswire

Signify share repurchase periodic update

Share

Press Release

August 31, 2020

Signify share repurchase periodic update

Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 393,072 shares in the period August 24 to August 28, 2020. The shares were repurchased at an average price of EUR 28.79 per share and an aggregate amount of EUR 11.3 million.

These repurchases were made as part of the company’s repurchase program, which was announced on July 30, 2020. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 1,122,500 shares for a total consideration of EUR 31.2 million.

Details on the share buyback transactions can be found here.

--- END ---

For further information, please contact:

Signify Investor Relations
Rogier Dierckx
Tel: +31 6 1138 4609
E-mail: rogier.dierckx@signify.com

Signify Corporate Communications
Elco van Groningen
Tel: +31 6 1086 5519
E-mail: elco.van.groningen@signify.com

About Signify

Signify (Euronext: LIGHT) is the world leader in lighting for professionals and consumers and lighting for the Internet of Things. Our Philips products, Interact connected lighting systems and data-enabled services, deliver business value and transform life in homes, buildings and public spaces. With 2019 sales of EUR 6.2 billion, we have approximately 36,000 employees and are present in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We have been named Industry Leader in the Dow Jones Sustainability Index for three years in a row. News from Signify is located at the Newsroom, Twitter, LinkedIn and Instagram. Information for investors can be found on the Investor Relations page.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

EPH European Property Holdings Limited (EPH) announces plans to issue and offer up to 4,500,000 new ordinary shares23.11.2020 19:00:00 CETPress release

23 November 2020, Road Town, Tortola, BVI EPH European Property Holdings Ltd (the "Company"), an investment company listed on SIX Swiss Exchange which holds an extensive property portfolio with a total value of around USD 1.3 billion across Europe, announces its intention to issue and offer up to 4,500,000 new ordinary shares for a consideration equaling the last reported net asset value (as per 30 June 2020) in the amount of USD 38.82 per share (the "Offer Shares"). EPH will hold a virtual conference on Monday, 30 November 2020 at 3 pm CET to explain details of the capital increase and the company's strategy. You are welcome to register for this event. Please contact corporatefinance@valartis.chto receive dial-in data. The proceeds from the issue of the Offer Shares will be used for funding our future growth through, including, without limitation, the following: acquisition of additional income generating or to be developed commercial properties and investments in our existing real es

Idorsia announces positive results of the two Japanese registration studies with clazosentan23.11.2020 17:45:10 CETPress release

Clazosentan demonstrates significant reduction of vasospasm-related morbidity and all-cause mortality in patients following aneurysmal subarachnoid hemorrhage (aSAH)Clazosentan demonstrates significant reduction of all-cause morbidity and mortality in patients following aSAH in a pre-planned pooled analysis of data from both studies.Idorsia Japan to file New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021Global Phase 3 study “REACT” investigating the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH continues to actively recruit Allschwil, Switzerland – November 23, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the Japanese registration program investigating clazosentan in adult Japanese patients post-aSAH. The program consisted of two double-blind, randomized, placebo-controlle

Saniona rapporterar positiva topline-resultat från den öppna förlängningen av Fas 2-studien med Tesomet mot hypotalamisk fetma23.11.2020 17:00:00 CETPressemelding

PRESSMEDDELANDE 23 november 2020 Tesomet tolererades väl av patienterna med hypotalamisk fetma under hela den 48 veckor långa studien (24 veckor dubbelblind del följt av 24 veckor öppen förlängning). Inga kliniskt betydelsefulla skillnader kunde noteras avseende hjärtfrekvens eller blodtryck och samtliga patienter som påbörjade den öppna förlängningsstudien slutförde också studien.De patienter som fick Tesomet under hela den 48 veckor långa studietiden påvisades statistiskt signifikanta och kliniskt meningsfulla minskningar av kroppsvikt och midjeomfång från baseline till vecka 48, liksom förbättrad glykemisk kontroll. De förbättringar som observerades under den första dubbelblinda delen av studien bibehölls under hela den senare öppna förlängningsstudien. Även för de patienter som fick placebo under den dubbelblinda delen av studien och sedan Tesomet under den öppna förlängningsstudien påvisades minskningar av kroppsvikt och midjeomfång efter övergången till Tesomet.Saniona kommer att

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity23.11.2020 17:00:00 CETPress release

PRESS RELEASE November 23, 2020 Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period. Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 202

Incap Corporation: Notification in accordance with chapter 9, section 10 of the securities market act on a change in holdings (Oy Etra Invest Ab)23.11.2020 16:30:00 CETPress release

Incap Corporation Stock Exchange Release 23 November 2020 at 5.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Oy Etra Invest Ab) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Erkki Etola and the entities controlled by him (Tiiviste-Group Oy and Oy Etra Invest Ab) in Incap Corporation (FI0009006407) has increased over 20 percent threshold. Shareholder: Erkki Etola and entities controlled by him Position of previous notification: 19.20 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 1,327,333 shares, i.e. 22.81 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. After November 20, 2020, Erkki Etola's direct holding of shares and v

USD TENDER OPERATION ANNOUNCEMENT23.11.2020 16:20:00 CETPress release

Bid date, 2020-11-25Bid Date2020-11-25Bid times14.00-14.30 (CET/CEST) on the Bid dateOfferent AmountUSD 10 billionMaximum Permitted Volume of BidsUSD 4 billion from an individual institutionSettlement Date2020-11-30Minimum Permitted Bid Volume100 USD million per bidMaximum Allocation40 per cent of the Offerend amountAllocation timeNo later than 15.00 (CET/CEST) on the Bid dateMaturity Date2021-02-22Maximum Number of Bids10 per individual institutionLowest Interest Supplement0,25 percentage pointsConfirmation of bids to e-maileol@riksbank.se Stockholm, 2020-11-23 This is a translation of the special terms and conditions published on riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail.